CabOSTar_Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcomahttps://www.nct-dresden.de/de/trials/900-000002485https://www.nct-dresden.de/@@site-logo/logo-nct.svg
CabOSTar_Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Sarkome
Knochensarkome
Systemtherapie ab 2. Linie (metastasierte Erkrankung)